Real-world experience may guide intravitreal injection treatments.

The article discusses the use of steroid implants in the treatment of patients with diabetic macular edema (DME). Topics covered include the approval of intravitreal injection implants, Ozurdex or dexamethasone from pharmaceutical firm Allergan and fluocinolone acetonide or Iluvien from biopharmaceutical firm Alimera Sciences, by the U.S. Food and Drug Administration (FDA) for DME, and the views of Dr. Andrew Moshfeghi on the use of anti-vascular endothelial growth factor (VEGF) agents.